• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Innoviva, Inc.

    Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Innoviva to Participate in Upcoming Investor Conferences
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Innoviva to Participate in the BofA Securities Health Care Conference
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023
    From Innoviva, Inc.
    Via Business Wire
    Innoviva to Participate in the Cantor Global Healthcare Conference
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Innoviva Appoints Stephen Basso as Chief Financial Officer
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Innoviva Announces Retirement of Board Chairman
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Innoviva Stock Trading Halted Today
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Innoviva Completes Acquisition of La Jolla Pharmaceutical
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA LJPC
    Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 million milestone payment
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Innoviva Completes Acquisition of Entasis Therapeutics
    From Innoviva, Inc.
    Via Business Wire
    Tickers INVA
    Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.
    From Innoviva, Inc.
    Via Business Wire
    Tickers ETTX INVA
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.